Fig. 7

Relationships between Pyrsig score and responsiveness to anti-PD-L1 immunotherapy. A, B Relative distribution of TIDE (A) and IPS (B) in different Pyrsig scores in TCGA-OV, respectively. C, D The correlation of anti-PD-L1 responsiveness with low and high Pyrsig scores in IMvigor210 database. E, F The correlation of immune phenotypes with low and high Pyrsig scores in IMvigor210 database. (G-J) The correlation of PD-L1 expression on tumor cells (G, H) and immune cells (I, J) with low and high Pyrsig scores in IMvigor210 database. K OS of patients with different Pyrsig scores in IMvigor210 database by Kaplan-Meier curve. L OS of patients with low and high neoantigen burden in IMvigor210 database by Kaplan-Meier curve. M OS of patients with anti-PD-L1 immunotherapy stratified by both Pyrsig score and neoantigen burden with Kaplan-Meier curves. SD: stable disease; PD: progressive disease; CR: complete response; PR: partial response. H: high; L: Low; Neo: neoantigen burden